The Technical Analyst
Acasti Pharma Inc [ACST]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Acasti Pharma Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-2.03% $2.90
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 27.26 mill |
| EPS: | -5.68 |
| P/E: | -0.510 |
| Earnings Date: | Jun 21, 2024 |
| SharesOutstanding: | 9.40 mill |
| Avg Daily Volume: | 0.0263 mill |
| RATING 2024-04-26 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.510 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.09x |
| Company: PE -0.510 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$2.70 (-6.96%) $-0.202 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.79 - 3.01 ( +/- 3.79%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-05 | Delaversano Robert J | Sell | 42 000 | Stock Options (Right to Buy) |
| 2023-12-19 | Kavuru Vimal | Buy | 10 000 | Stock Options (Right to Buy) |
| 2023-12-19 | Kottayil George | Buy | 22 500 | Stock Options (Right to Buy) |
| 2023-12-19 | Neugeboren Edward | Buy | 22 500 | Stock Options (Right to Buy) |
| 2023-12-19 | Davis A Brian | Buy | 22 500 | Stock Options (Right to Buy) |
| INSIDER POWER |
|---|
| 88.60 |
| Last 64 transactions |
| Buy: 4 252 386 | Sell: 2 858 533 |
Forecast:
16:00 - $2.90
Live Trading Signals (every 1 min)
Forecast
1: 14:37 - $2.93
Forecast 2: 15:27 - $2.96
Forecast 3: 16:00 - $2.90
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $2.90 (-2.03% ) |
| Volume | 0.0038 mill |
| Avg. Vol. | 0.0263 mill |
| % of Avg. Vol | 14.51 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ACST
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ACST
Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Latest Press Releases
2024-02-12 08:00:00 - Press Release
Acasti Announces Third Fiscal Quarter 2024 Financial Results And Business Highlights
Princeton, n.j., feb. 12, 2024 (globe newswire) -- acasti pharma inc. (nasdaq: acst) (acasti or the company), a late-stage, biopharma company advancing gtx-104, its novel formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (asah), today announced financial results and business highlights for the quarter ended december 31, 2023.
2024-02-01 08:00:00 - Press Release
Acasti Announces Poster Detailing Its Gtx-104 Strive-on Trial
Accepted for presentation at the 2024 international stroke conference accepted for presentation at the 2024 international stroke conference
2023-12-13 08:00:00 - Press Release
Acasti To Participate In Upcoming San Francisco Investor Conferences In January 2024
Princeton, n.j., dec. 13, 2023 (globe newswire) -- acasti pharma inc. (nasdaq: acst) (acasti or the company), a late-stage, biopharma company advancing gtx-104, its novel intravenous formulation of nimodipine being developed to address the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (asah), today announced that chief executive officer prashant kohli will participate in the following investor and industry networking events in san francisco, california during the week of january 7-12, 2024.
2023-11-13 08:00:00 - Press Release
Acasti Announces Second Quarter 2024 Financial Results And Business Highlights
Princeton, n.j., nov. 13, 2023 (globe newswire) -- acasti pharma inc. (nasdaq: acst) (acasti or the company), a late-stage, biopharma company advancing gtx-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (asah), today announced financial results and business highlights for the quarter ended september 30, 2023.
2023-10-23 08:00:00 - Press Release
Acasti Announces Dosing Of First Patient In Gtx-104 Strive-on Trial
Princeton, n.j., oct. 23, 2023 (globe newswire) -- acasti pharma inc. (nasdaq: acst) (acasti or the company), a late-stage, biopharma company advancing gtx-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (asah), today announced enrollment of the first patient in the company's pivotal phase 3 strive-on safety trial (the strive-on trial–nct05995405). uthealth houston is the first site to enroll an asah patient in the strive-on trial.
Latest News
2023-12-13 08:00:00 - GlobeNewsWire
Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024
PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel intravenous formulation of nimodipine being developed to address the high unmet medical needs for a rare disease, aneurysmal Subarachnoid Hemorrhage (aSAH), today announced that Chief Executive Officer Prashant Kohli will participate in the following investor and industry networking events in San Francisco, California during the week of January 7-12, 2024.
2023-09-06 08:00:00 - GlobeNewsWire
Acasti to Participate in the H.C. Wainwright Global Investment Conference
PRINCETON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that the Company's management will be participating in the 25th Annual H.C. Wainwright Global Investment Conference, to be held September 11-13 , 2023 in New York, NY.
2023-08-09 16:05:00 - GlobeNewsWire
Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting
PRINCETON, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) ("Acasti" or the "Company"), a late-stage, biopharma company advancing GTX-104 its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that a poster presenting a pharmacokinetic comparison of GTX-104 with oral nimodipine has been accepted for presentation at the 2023 Neurocritical Care Society (NCS) annual meeting, to be held in Phoenix, AZ August 15-18, 2023.
2023-02-28 11:18:55 - Zacks Investment Research
Has Acasti Pharma (ACST) Outpaced Other Medical Stocks This Year?
Here is how Acasti Pharma (ACST) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.
2023-02-14 15:53:09 - Seeking Alpha
Acasti Pharma Inc. (ACST) Q3 2023 Earnings Call Transcript
Acasti Pharma Inc. (NASDAQ:ACST ) Q3 2023 Earnings Conference Call February 14, 2023 1:00 PM ET Company Representatives Jan D'Alvise - President, Chief Executive Officer Brian Ford - Chief Financial Officer Pierre Lemieux - Chief Operating and Scientific Officer, Co-Founder Prashant Kohli - Chief Commercial Officer Robert Blum - Lytham Partners Conference Call Participants Leland Gershell - Oppenheimer Oren Livnat - H.C. Wainwright Operator Good day, and welcome to the Acasti Pharma Reports Third Quarter of Fiscal Year 2023 Financial Results and Business Update Call.
2023-01-24 16:15:00 - GlobeNewsWire
Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31
LAVAL, Québec, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced Jan D'Alvise, CEO, will present and host one-on-one meetings with investors at the Lytham Partners Investor Select Conference, taking place virtually on January 31, 2023.
2023-01-13 09:00:00 - GlobeNewsWire
Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18
LAVAL, Québec, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced Jan D'alvise, CEO, will present and host one-on-one meetings with investors at the Sidoti January Virtual Investor Conference, taking place on January 18-19, 2023.
2023-01-05 09:00:00 - GlobeNewsWire
Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures
LAVAL, Québec, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced that it will host a conference call on Tuesday, January 10, 2023 at 4:30 p.m. ET to review the recently reported preliminary topline results from two separate Phase 1 pharmacokinetic (PK) studies for GTX-101 and GTX-102. Both studies successfully met all target outcome measures.
2022-12-28 13:16:55 - PennyStocks
Best Penny Stocks To Buy Now? 4 Stocks Under $4 To Watch
2022-11-14 23:23:11 - Seeking Alpha
Acasti Pharma Inc. (ACST) Q2 2023 Earnings Call Transcript
Acasti Pharma Inc. (NASDAQ:ACST ) Q2 2023 Earnings Conference Call November 14, 2022 1:00 PM ET Company Participants Robert Blum - Lytham Partners, IR Jan D'Alvise - President & CEO Brian Ford - CFO Prashant Kohli - Chief Commercial Officer Conference Call Participants Leland Gershell - Oppenheimer Sahil Kazmi - B. Riley Securities Operator Good day, and welcome to the Acasti Pharma Second Quarter 2023 Earnings Event Call.